Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Etropal ADXBUL:ETR 50 PB Ratio is 3.00 as of Aug. 09, 2026, which is 66% below its 10-year median of 8.84. GuruFocus rates XBUL:ETR with a GF Score™ of 50/100 and a GF Value™ of €8.71 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 785 Medical Devices & Instruments companies, Etropal AD ranks worse than 63.44% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-09), Etropal AD's share price is €2.66. Etropal AD's Book Value per Share for the quarter that ended in Dec. 2025 was €0.89. Hence, Etropal AD's PB Ratio of today is 3.00.
The historical rank and industry rank for Etropal AD's PB Ratio or its related term are showing as below:
XBUL:ETR'
s PB Ratio Range Over the Past 10 Years
Min: 2.6 Med: 8.84 Max: 11.04
Current: 3
During the past 13 years, Etropal AD's highest PB Ratio was 11.04. The lowest was 2.60. And the median was 8.84.
XBUL:ETR's PB Ratio is ranked worse than 63.44% of 785
companies
in the Medical Devices & Instruments industry
Industry Median: 2.11
vs XBUL:ETR: 3.00
During the past 12 months, Etropal AD's average Book Value Per Share Growth Rate was 4.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 1.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 6.90% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 6.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Etropal AD was 17.60% per year. The lowest was -3.40% per year. And the median was 0.20% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Etropal AD PB Ratio Related Terms
Etropal AD PB Ratio Historical Data
* Premium members only.
The historical data trend for Etropal AD's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Etropal AD's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Etropal AD PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Etropal AD's PB Ratio distribution charts can be found below:
* The bar in red indicates where Etropal AD's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Etropal AD's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Etropal AD (XBUL:ETR) has a PB Ratio of 3.00 as of Aug. 09, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Etropal AD and its competitors. This is 66% below median its historical median of 8.84. Over the past decade, Etropal AD's PB Ratio has ranged from 2.60 to 11.04. According to the industry distribution chart, Etropal AD ranks #498 out of 785 companies in the Medical Devices & Instruments industry, placing it in the top 63.4%.
Is Etropal AD's PB Ratio too high?
Etropal AD's current PB Ratio of 3.00 is 66% below median its 10-year median of 8.84. Over the past 10 years, this metric has ranged from a low of 2.60 to a high of 11.04. The Medical Devices & Instruments industry median PB Ratio is 2.11. Etropal AD's value of 3.00 is 42.2% above this industry median. Based on the distribution chart, Etropal AD ranks #498 out of 785 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Etropal AD has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Etropal AD's PB Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Etropal AD ranks #498 out of 785 companies for PB Ratio. This places Etropal AD in the lower half of its industry. The industry median PB Ratio is 2.11. Etropal AD's value of 3.00 is 42.2% above this benchmark. Historically, Etropal AD's own PB Ratio has ranged from 2.60 to 11.04 over the past decade. While the company's 10-year median is 8.84 vs. the industry median of 2.11, Etropal AD has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.11, based on 785 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Etropal AD's current PB Ratio of 3.00 is 42.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Etropal AD and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Etropal AD's current PB Ratio is 3.00, which is 66% below median its own 10-year median of 8.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Etropal AD stock overvalued right now?
Based on GuruFocus' analysis, Etropal AD (XBUL:ETR) is currently considered Significantly Undervalued. The stock's GF Value™ is €8.71, compared to a current price of €2.66 — trading 69.5% below its estimated fair value. The current PB Ratio is 3.00, which is 66% below median its 10-year median of 8.84 and 42.2% above the Medical Devices & Instruments industry median of 2.11. Etropal AD's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Etropal AD (XBUL:ETR), the current PB Ratio is 3.00 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Etropal AD (XBUL:ETR) Overvalued in 2026?
Based on GuruFocus' analysis, Etropal AD stock appears to be undervalued.
The current stock price of €2.66 is trading 69.5% below its estimated GF Value™ of €8.71.
GuruFocus considers Etropal AD to be Significantly Undervalued.
Key valuation signals for XBUL:ETR:
PB Ratio: 3.00 (66% below median its 10-year median of 8.84)
GF Value™: €8.71 vs. price of €2.66 (69.5% below fair value)
Industry Position: 42.2% above the Medical Devices & Instruments median (#498 of 785)
No single metric tells the full story. See the XBUL:ETR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Etropal AD is engaged in the business of manufacturing medical accessories. The product portfolio includes fistula needles, blood taking sets, transfusion and infusion sets, catheters and tubes, urine collecting bags, colostomy bags, among others. The company also produces hip - joint endoprosthesis and instruments of implantation.
50GF Score
Get the complete analysis for XBUL:ETR
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XBUL:ETR has been successfully added to your 
